Table 2.
Main clinical characteristics of patients with RFC and with IFC.
| RFC n = 19 | IFC n = 16 | P-value | |
|---|---|---|---|
| Age, mean ± SD | 62 ± 13 | 63 ± 11 | 0.89 |
| Gender, M/F | 13/6 | 10/7 | 0.73 |
| CV risk factors | |||
| Smoke, (%) | 7 (41) | 10 (62) | 0.20 |
| Diabetes, (%) | 5 (26) | 2 (12) | 0.41 |
| Hypertension, (%) | 14 (74) | 11 (69) | 1.00 |
| Dyslipidemia, (%) | 10 (53) | 6 (37) | 0.50 |
| Obesity, (%) | 4 (21) | 4 (25) | 1.00 |
| Family history, (%) | 10 (53) | 2 (12) | 0.03 |
| Medical therapy | |||
| DAPT, (%)# | 6 (32) | 9 (56) | 0.18 |
| ASA, (%) | 12 (63) | 12 (75) | 0.50 |
| Clopidogrel, (%) | 3 (15) | 3 (19) | 0.32 |
| Prasugrel, (%) | 0 (0) | 0 (0) | – |
| Ticagrelor, (%) | 5 (26) | 7 (31) | 0.53 |
| Anticoagulants, (%) | 2 (10) | 2 (12) | 0.52 |
| Beta-Blockers, (%) | 6 (32) | 9 (56) | 0.24 |
| Diuretics, (%) | 4 (21) | 4 (25) | 0.45 |
| ACE-I, (%) | 6 (32) | 4 (25) | 0.33 |
| ARBs, (%) | 9 (47) | 6 (38) | 0.31 |
| Statins, (%) | 6 (32) | 7 (43) | 0.47 |
| Ca-antagonists, (%) | 2 (10) | 5 (31) | 0.21 |
| Nitrates, (%) | 0 (0) | 1 (6) | 0.46 |
| Insulin, (%) | 0 (0) | 1 (6) | 0.46 |
| Oral antidiabetic, (%) | 3 (16) | 2 (12) | 0.39 |
#
These data refer to the time of the enrollment of the patient and blood withdrawal. At the time of coronary angiography, all the patients with NSTEMI were on DAPT according to current guidelines. Bold values denote statistical significance. ACE-I, ACE-inhibitors; ARBs, angiotensin II receptor blockers; ASA, Aspirin; CV, cardiovascular; DAPT, dual antiplatelet therapy; IFC, intact fibrous cap; and RFC, ruptured fibrous cap.